SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists
5 references·0 citing·14 second hop
Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists (2023)Patents and Regulatory Exclusivities on G…Coverage, Formulary Restrictions, and Out-of-Pocket Costs for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Medicare Part D Program (2020)Coverage, Formulary Restricti…Tertiary patenting on drug–device combination products in the United States (2018)Tertiary patenting on drug–de…Determinants of Market Exclusivity for Prescription Drugs in the United States (2017)Determinants of Market Exclus…The High Cost of Prescription Drugs in the United States (2016)The High Cost of Prescription…U.S. Government Accountability Office (2013)U.S. Government Accountabilit…Diagnosing the decline in pharmaceutical R&D efficiency (2012)American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options (2015)Innovation in the pharmaceutical industry: New estimates of R&D costs (2016)The high price of anticancer drugs: origins, implications, barriers, solutions (2017)Financial toxicity in cancer care: Prevalence, causes, consequences, and reduction strategies (2019)How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment (2021)Generic Drug Industry Dynamics (2005)Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000–2009 (2010)Generic competition and market exclusivity periods in pharmaceuticals (2007)Combination therapy patents: a new front in evergreening (2021)Out‐of‐Pocket Annual Health Expenditures and Financial Toxicity From Healthcare Costs in Patients With Heart Failure in the United States (2021)Detention of Immigrant Children (2017)Protect, Serve, and Deport: The Rise of Policing as Immigration Enforcement (2017)Costs of Drug Development and Research and Development Intensity in the US, 2000-2018 (2024)
this work references cited by second hop

References

  • 2013U.S. Government Accountability Office997 cited
  • 2016The High Cost of Prescription Drugs in the United States591 cited
  • 2020Coverage, Formulary Restrictions, and Out-of-Pocket Costs for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Medicare Part D Program99 cited
  • 2017Determinants of Market Exclusivity for Prescription Drugs in the United States71 cited
  • 2018Tertiary patenting on drug–device combination products in the United States24 cited

Cited by

No citing works inside the corpus for this window.

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work